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The Journal of Immunology
G2A Signaling Dampens Colitic Inflammation via Production
of IFN-g
S. Courtney Frasch,* Eo´in N. McNamee,† Douglas Kominsky,†,1 Paul Jedlicka,‡
Claudia Jakubzick,*,x Karin Zemski Berry,{ Matthias Mack,‖ Glenn T. Furuta,#,**
James J. Lee,†† Peter M. Henson,* Sean P. Colgan,†,2 and Donna L. Bratton*,2
Proinflammatory consequences have been described for lysophosphatidylcholine, a lipid product of cellular injury, signaling via the
G protein–coupled receptor G2A on myeloid and lymphoid inflammatory cells. This prompted the hypothesis that genetic deletion
of G2A would limit intestinal inflammation in a mouse model of colitis induced by dextran sodium sulfate. Surprisingly, G2A2/2
mice exhibited significantly worsened colitis compared with wild-type mice, as demonstrated by disease activity, colon shortening,
histology, and elevated IL-6 and IL-5 in colon tissues. Investigation of inflammatory cells recruited to inflamed G2A2/2 colons
showed significantly more TNF-a+ and Ly6ChiMHCII2 proinflammatory monocytes and eosinophils than in wild-type colons.
Both monocytes and eosinophils were pathogenic as their depletion abolished the excess inflammation in G2A2/2 mice. G2A2/2
mice also had less IFN-g in inflamed colon tissues than wild-type mice. Fewer CD4+ lymphocytes were recruited to inflamed
G2A2/2 colons, and fewer colonic lymphocytes produced IFN-g upon ex vivo stimulation. Administration of IFN-g to G2A2/2
mice during dextran sodium sulfate exposure abolished the excess colitic inflammation and reduced colonic IL-5 and eosinophil
numbers to levels seen in wild-type mice. Furthermore, IFN-g reduced the numbers of TNF-a+ monocyte and enhanced their
maturation from Ly6ChiMHCII2 to Ly6CintMHCII+. Taken together, the data suggest that G2A signaling serves to dampen
intestinal inflammation via the production of IFN-g, which, in turn, enhances monocyte maturation to a less inflammatory
program and ultimately reduces eosinophil-induced injury of colonic tissues. The Journal of Immunology, 2016, 197: 1425–1434.
T
he inflammatory bowel diseases (IBD), including both
ulcerative colitis and Crohn’s disease, are debilitating
mucosal disorders of unknown etiology (1). The most
recent evidence suggests IBD results from an inappropriately di-
rected inflammatory response to the intestinal microbiota in a
genetically susceptible host. Epithelial cells are crucial in the
maintenance of colonic tissue homeostasis, as IBD is character-
ized by a breakdown of the intestinal epithelial barrier leading to
increased exposure of the mucosal immune system to antigenic
luminal material. Because the epithelium functions as the critical
interface between the intestinal lumen and the subepithelial mu-
cosa, it is thereby anatomically positioned as a central coordinator
of mucosal inflammatory response.
Studies to date indicate that cytokines and chemokines that are
produced locally at sites of inflammation play an important role in
onset and progression of IBD. IFN-g, present in IBD, has been
shown to have a proinflammatory role in a number of autoimmune
and inflammatory diseases (1, 2). The dextran sodium sulfate
(DSS) model of murine colitis results from direct epithelial injury,
followed by recruitment of inflammatory cells and their inappro-
priate response to the microflora of the gut (3). The acute phase is
characterized by the production of proinflammatory cytokines,
including IFN-g, similar to that observed in human IBD (4–7).
The G protein–coupled receptor, Gpr132 (G2A), is expressed
on most leukocytes, for example, lymphocytes, monocytes, and
granulocytes [www.immgen.org (8)]. Signaling by G2A is poorly
understood and varies widely depending on its activator and the
responding cell type and inflammatory context (8). One such
stimulant is lysophosphatidylcholine (lysoPC), a lipid produced by
injured epithelium, for example, in the airways (9, 10) and colon
(11, 12). LysoPC signaling through G2A induces chemotaxis of
monocytes, macrophages, and lymphocytes (13–15) and enhances
the production of reactive oxygen species by phagocytes (16, 17)
and IFN-g from lymphocytes (18).
Given the observations noted above that G2A signaling
heightens inflammatory cell recruitment and host defense re-
sponses, we hypothesized that deficiency of G2A, or antagonism of
its signaling, would be beneficial in colitis. However, contrary to
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our hypothesis, genetic deficiency of G2A resulted in significantly
worsened colitis in the knockout (G2A2/2) mice compared with
wild-type (WT) animals. These data demonstrate that whereas
production of lysoPC was similar in both G2A2/2 and WT mice
during DSS exposure, deficient IFN-g production within colon
tissues of the G2A2/2 mice led to worsened injury that was rec-
tified by exogenous administration of IFN-g. These data support
the unexpected conclusion that signaling via the G protein–coupled
receptor G2A serves to counterbalance overexuberant innate immune
cell injury in DSS colitis via the enhanced production of IFN-g.
Materials and Methods
Reagents
Anti-CD45 BV510 or allophycocyanin, anti-Ly6C allophycocyanin-Cy7,
anti-Ly6G PE, anti-MHCII BV421, anti-CD11b PerCPCy5.5, anti-CD11c
PE-Cy7, anti–IFN-g PE, anti–TNF-a allophycocyanin, anti-CD3 PerCPCy5.5,
anti-CD8 PE, anti-CD4 allophycocyanin-Cy7, anti-NKp46 PE-Cy7, and anti-
B220 Alexa488 were from BioLegend (San Diego, CA). Anti-CD16/32 (Fc-
block), anti-SiglecF PE, and anti-F4/80 Alexa488 were from BD Biosciences
(San Diego, CA). Blue fixable Live/Dead was from Invitrogen. Anti-CCR2
(clone MC-21) was provided by M. Mack (University of Regensburg,
Regensburg, Germany). Anti–IL-5 (clone TRFK5) was provided by J. Lee
(Mayo Clinic, Scottsdale, AZ). Mouse rIFN-g was from R&D Systems.
Collagenase D was from Roche Diagnostics (Indianapolis, IN), and col-
lagenase VIII was from Sigma-Aldrich (St. Louis, MO). The 1-oleoyl-2-
hydroxy-sn-glycerol-3-phosphocholine (LPC) was from Avanti Polar
Lipids (Alabaster, AL).
Mice
Male and female C57BL/6 (WT) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were generated from a breeding colony at
National Jewish Health (Denver, CO). G2A2/2 breeder pairs on a C57BL/6
background were a gift of C. Hedrick (La Jolla Institute for Allergy and
Immunology, La Jolla, CA) and were bred in house. All animals received
care in accordance with the guidelines of the Institutional Animal Care and
Use Committee and were maintained on food and water ad libitum. Mice
between the ages of 8 and 12 wk were used and were age and gender matched
for all experiments. WT and G2A2/2 mice were cohoused for 7–10 d prior to
induction of colitis. Preliminary experiments demonstrated that the results
following 7-d cohousing were identical to those following 14 d of cohousing.
Induction of colitis and treatments
Experimental colitis was induced in mice by adding 3% (w/v) DSS (m.w.
36,000–50,000; MP Biomedicals, Santa Ana, CA) to drinking water for
various numbers of days (2–6 d, as indicated). Fresh DSS solutions were
replaced at 3 d. The animals were monitored daily for disease activity
using the parameter of weight loss, stool consistency, and fecal blood.
Disease activity index was calculated, as described by Cooper et al. (19),
as the sum of scores of stool consistency (0 = normal; 1 = near normal; 2 =
loose stool; 3 = very loose stool; 4 = diarrhea) and establishment of ulceration
of the colon as detected by blood in the feces (0 = negative; 1 = near negative;
2–3 = positive; 4 = gross bleeding) for a maximum score of 8. On the final
day, mice were humanely euthanized and colons were harvested. Colon
length was measured as an indicator of disease severity. For depletion of
monocytes, 20 mg anti-CCR2 (clone MC-21) or isotype control was injected
i.p. on consecutive 5 d starting at day 1 after administration of DSS. For
depletion of eosinophils, 200 mg anti–IL-5 (clone TRFK5) or isotype control
was injected i.p. on consecutive 5 d starting on day 1 after administration of
DSS. For IFN-g restoration experiments, mice received 5 mg mouse rIFN-g
(R&D Systems) i.p. on days 3 and 5 after administration of DSS.
Histology
Sections from the distal colon of each mouse were fixed in 10% formalin
before staining with H&E. All histological quantitation was performed
blinded by a trained pathologist (P.J.). Colitis severity was determined by
three independent parameters, as described previously (20). Severity of
inflammation (0–3: none, slight, moderate, severe), extent of injury (0–3:
none, mucosal, mucosal and submucosal, transmural), and crypt damage
(0–4: none, basal one-third damaged, basal two-thirds damaged, only
surface epithelium intact, entire crypt and epithelium lost). The score of
each parameter was multiplied by a factor reflecting the percentage of
tissue involvement (X1: 0–25%, X2: 26–50%, X3: 51–75%, X4: 76–
100%), and all numbers were summed for a total histologic index.
Isolation of colonic lamina propria leukocytes and splenocytes
Colons were opened longitudinally, flushed with PBS to remove contents, and
cut into 1-cm pieces. Epithelial cells were depleted by incubation in 15 mL
HBSS (Mediatech, Manassas, VA) supplemented with 15 mM HEPES (pH
7.2), 2 mM EDTA and 2% heat-inactivated FBS (Atlanta Biologicals,
Lawrenceville, GA), 100 mg/ml streptomycin, and 100 U/ml penicillin at
37˚C for 40 min with constant shaking. The epithelial cell–depleted colon
tissue was washed in PBS to remove the EDTA, minced, and digested in
10 mL RPMI 1640 supplemented with 15 mM HEPES (pH 7.2), 5% heat-
inactivated FBS (Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine,
100 mg/ml streptomycin, 100 U/ml penicillin, 1.2 mg/ml collagenase D, and
0.85 mg/ml collagenase VIII for 30 min at 37˚C with constant shaking.
Digested colon cells were passed through a 100-mm filter to remove undi-
gested tissue, and the cells were centrifuged at 200 3 g for 10 min. Total
cells from colon digests were determined by coulter counts, and cells were
either cultured ex vivo or stained for analysis by flow cytometry (see below).
After the spleen was harvested from untreated mice, a single-cell sus-
pension was obtained by manually disrupting spleens through a 70-mm cell
strainer (BD Falcon, Bedford, MA) with HBSS. Following lysis of RBCs,
the splenocytes were refiltered with a 40-mm cell strainer and resuspended
at 2.5 3 106 cells/ml in RPMI 1640 supplemented with 15 mM HEPES
(pH 7.2), 0.1% BSA, 2 mM L-glutamine, 100 mg streptomycin, and 100
U/ml penicillin and stimulated, as described below.
Flow cytometry
Isolated lamina propria cells were incubated with Fc block and stained with
Abs, and flow cytometry was performed on a BDLSRII or BD LSRFortessa.
Data were analyzed on FlowJo X v.10.0.7 (Tree Star). See Supplemental
Fig. 1 for gating strategy. Briefly, immune cell subsets were identified
among live CD45+ cells after doublet exclusion.
For determination of colonic tissue or colonic vascular localization of
lamina propria leukocytes, 5 ml anti-CD45 allophycocyanin in 200 ml PBS
was injected i.v. 5 min before euthanasia. This method allows for the
differential identification of cells that are extravascular (at least excluded
from Ab labeling) and most likely located within the colonic tissue versus
cells that are within the colonic vascular lumen. Total cell subsets were
determined by multiplying the percentage of the cell subset, as determined
by flow cytometry, by the total cell counts.
Culture and stimulation of colon tissue digests and spleen cells
For culture ex vivo, 1 3 106 digested colon cells in 200 ml RPMI 1640
supplemented with 10% heat-inactivated FBS (Atlanta Biologicals, Law-
renceville, GA), 15 mM HEPES (pH 7.4), 2 mM L-glutamine, 100 mg/ml
streptomycin, and 100 U/ml penicillin were left unstimulated or stimulated
with 13 cell stimulation mixture (PMA plus ionomycin; eBioscience, San
Diego, CA) in the presence or absence of 13 protein transport inhibitor
(brefeldin A and monensin; eBioscience) for 4 h at 37˚C. Cell-free su-
pernatants were analyzed for IFN-g or TNF-a by ELISA (ELISA Tech,
Aurora, CO). Cells treated with protein transport inhibitor were stained for
surface markers, fixed, and permeabilized with the Fox P3 permeabiliza-
tion kit (eBioscience), according to the manufacturer’s instructions for
intracellular staining of IFN-g and TNF-a. For ex vivo stimulation of naive
spleen cells, 0.5 3 106 spleen cells in 200 ml RPMI 1640 supplemented
with 0.1% BSA, 15 mM HEPES (pH 7.4), 2 mM L-glutamine, 100 mg/ml
streptomycin, and 100 U/ml penicillin were left unstimulated or stimulated
with 0.53 stimulation mixture in the absence or presence of 10 mM LPC.
A 103 stock of LPC was made by drying the LPC under a flow of nitrogen
in a glass tube and resuspending in RPMI 1640 supplemented with 0.1%
BSA. LPC was dissolved by sonication in a water bath sonicator. LPC was
added simultaneously with the stimulation mixture. Cell-free supernatants
were analyzed for IFN-g by ELISA (ELISA Tech).
Cytokine determinations
Proinflammatory cytokines were measured by using the MesoScale Dis-
covery Platform (Proinflammatory Panel 1; MSD, Rockford, MD) in serum
obtained following cardiac puncture or homogenates from sections of distal
colon, according to the manufacturer’s instructions.
Quantitative PCR
Sections from distal colon were snap frozen and stored at 280˚C. Total
RNA was isolated using the Qiagen mini RNA isolation kit, according to
the manufacturer’s instructions, and reverse transcribed using iScript
cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Real-time quantitative PCR
was performed, and data were normalized to GusB and calculated as rel-
ative quantity (22DDCt, where Ct is cycle threshold for each sample). The
indicated forward and reverse primer pairs were purchased from Bio-Rad.
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Lysophospholipid measurement
Colon tissues were collected, weighed, and homogenized in MeOH/water
(50:50). Lysophosphatidylcholine (lysoPC) internal standard (17:1/OH-
phosphatidylcholine) was added, and total lipids were extracted by the
method of Bligh and Dyer (21). The organic layer was collected and
brought to dryness. Phospholipid classes were separated by application to
an aminopropyl SepPak (NH2-DSC) column, and lysoPC was eluted with
MeOH. LysoPC was measured in positive ion mode by precursors of m/z
184 by liquid chromatography–tandem mass spectrometry, as previously
described (22). For lysophosphatidylserine (lysoPS) measurements, colon
tissues were collected, weighed, minced, and extracted in MeOH. LysoPS
internal standard (17:1/OH-phosphatidylserine) was added, and insoluble
material was centrifuged at 10,0003 g for 10 min. The MeOH supernatant
was applied to an aminopropyl SepPac (NH2-DSC) column to separate
lipid classes, and lysoPS was eluted in ammonium hydroxide:MeOH 10:90
(v/v). LysoPS species were monitored by multiple reaction monitoring by
LC-MS/MS in negative ion mode, as described previously (23).
Statistical analysis
Data are presented as the means 6 SEM. Data represent three to five mice
per group and at least two independent experiments, unless otherwise
stated. Unpaired t test and one-way or two-way ANOVA test were used to
determine differences between groups, as indicated, where p , 0.05 was
considered significant (GraphPad Prism, La Jolla, CA).
Results
G2A deficiency does not alter intestinal homeostasis, but
results in worsened DSS-induced colitis
Initial studies confirmed the lack of intrinsic intestinal inflam-
mation in naive mice globally deficient for G2A. Histologic ex-
amination of colonic tissues showed no epithelial disruption or
obvious inflammation in either G2A2/2 or WT mice at baseline
(Supplemental Fig. 1A). Colon lengths and lysoPC levels were no
different between the two genotypes in the naive state
(Supplemental Fig. 1B, 1C). CD45+ cells in digests of colonic
tissues were examined by flow cytometry (see gating strategy in
Supplemental Fig. 1D). There were no baseline differences be-
tween the genotypes with regard to total numbers of macrophages,
monocytes, eosinophils, neutrophils, or lymphocytes (data not
shown). As expected, G2Awas expressed in the CD45+ cells from
WT colons, but not from the G2A2/2 colons, whereas isolated
colonic epithelial cells were negative for G2A expression in both
genotypes (data not shown). Total colon tissue was also analyzed
by quantitative PCR for proinflammatory cytokines, TNF-a, IL-6,
IL-1b, IFN-g, IL-12p70, IL-4, IL-13, and IL-5. Expression levels
were very low or undetectable, and no significant differences were
noted between the genotypes (data not shown).
In a well-described intestinal inflammation model (3, 4), DSS
(3%) was added to drinking water of both G2A2/2 and WT mice
and continued for 6 d. Disease activity was calculated using the
parameters of stool consistency and fecal blood, which were deter-
mined daily for each mouse, as described in experimental proce-
dures, with a maximum of 8 points (19). By day 3, disease activity
was evident in some mice of both genotypes and became more
severe with increasing duration of DSS exposure (Fig. 1A). Over
the time course of DSS exposure, G2A2/2 mice had significantly
greater disease activity scores than WT mice, and by day 6, had
overt diarrhea and bleeding into the stool. By day 6, most G2A2/2
mice had reached criteria to be euthanized. G2A2/2 mice tended to
lose more weight over the course of DSS exposure than WT mice.
On sacrifice at day 6, colon length was measured and found to be
significantly shorter in G2A2/2 mice than WT animals (Fig. 1B).
Histologic examination of colonic tissues at day 6 showed marked
inflammatory infiltrates in both genotypes and almost complete
loss of crypt architecture in the distal colons of the G2A2/2 mice
(Fig. 1C). Accordingly, blinded histologic scoring of colonic tissues
was significantly worse for G2A2/2 mice than for WT mice.
Recruited inflammatory cells (CD45+) were analyzed by flow
cytometry (Supplemental Fig. 1E gating strategy) following di-
gestion of the total colonic tissue. In DSS-induced colitis,
monocytes are a prominent recruited inflammatory cell and are
thought to be largely responsible for orchestrating responses to
commensal microbes that result in further colonic injury (24–27).
We found monocyte numbers to be increased in both genotypes
over time of DSS administration, but were significantly more
numerous in the G2A2/2 mice by day 6 (Fig. 2A). Because sig-
naling via G2A has been shown to mediate chemotaxis of in-
flammatory cells, including monocytes (8, 13), it was important to
determine whether the monocytes within the colons were similarly
distributed in the tissues versus vasculature in the two genotypes.
To this end, mice were injected i.v. with anti-CD45 just prior to
sacrifice to separately tag cells in the colonic intravascular com-
FIGURE 1. Loss of G2A receptor signaling exacerbates DSS-induced
colitis. (A) Disease activity (DAI) (left) and percentage of change in
weight (right) were determined daily during DSS administration, as de-
scribed in Materials and Methods. Dotted line indicates maximum DAI
score (left) or initial body weight at day 0 (right). (B) Colon length as a
measure of disease severity was determined on day 6 after 3% DSS ad-
ministration. Left, Representative photograph of WT and G2A2/2 colons.
Right, Summated colon lengths for each genotype. Dotted line represents
colon length of water control animals (see Supplemental Fig. 1B). (C) Left,
Representative histologic images of the distal colon on day 6 (original
magnification 310). Right, Quantitative total histologic index. Data rep-
resent mean 6 SEM, n = 15. *p , 0.05, **p , 0.01 versus WT.
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partment and thereby providing a snapshot of cells present in this
compartment. As shown in Fig. 2A, intravascular monocytes
(those labeling with anti-CD45) peaked at day 2 in both genotypes
and appeared to be equivalent. For the most part, monocytes were
extravascular (or sequestered from the Ab) in the inflamed colons
of both genotypes, demonstrating no obvious deficiency in re-
cruitment of monocytes or distribution in colonic tissues in G2A2/2
mice during DSS colitis. Eosinophils in colonic tissues during
DSS colitis mirrored monocytes (Fig. 2B). Their numbers rose
over the first 4 d of colitis similarly in both genotypes with few
appearing to be intravascular by anti-CD45 labeling. However,
significantly more eosinophils were present in the colons of
G2A2/2 mice by day 6. Recruited neutrophils were much fewer
than monocytes and eosinophils, and no differences between the
genotypes were evident (Fig. 2C). Unlike the other myeloid cell
types, intravascular neutrophils constituted a substantial propor-
tion of total neutrophils, ∼25–30% on days 2–4 of DSS exposure,
in both genotypes.
Although DSS-induced colitis develops independently of
lymphocytes in Rag2/2 mice (28), we did assess the lymphocyte
populations in the inflamed colons. A population of CD4 cells was
recruited to the colons of WT mice, but was strikingly deficient in
the colons of G2A2/2 mice throughout DSS exposure (Fig. 2D).
CD8 cells were present in colons of both genotypes, and no dif-
ferences in numbers were detected (Fig. 2E). NK cells (Fig. 2F) and
B cells (data not shown) were also recruited to inflamed colons in
similar numbers for both genotypes.
Colon tissues were assessed for several proinflammatory cyto-
kines and mediators reportedly produced during the acute-phase
DSS-induced colitis (4–7). Inflamed colon tissues harvested on
day 6 from G2A2/2 mice demonstrated significantly higher
amounts of IL-6 and IL-5 in comparison with WT (Fig. 3A). In
contrast, IFN-g levels in colon tissue were much lower in G2A2/2
mice (Fig. 3B). No differences between the genotypes were seen
for colon tissue levels of TNF-a, IL-12p70, IL-1b, CXCL1, or IL-
10 (data not shown). Message for CCL5, CCL11, CCL24, IL-13,
and IL-4 was determined by quantitative PCR, with no differences
detected between the genotypes (data not shown). LysoPC, asso-
ciated with injury of epithelium (11, 12), was also measured in
colonic tissues from both genotypes over time. Importantly,
LysoPC levels were elevated over baseline and appeared to peak at
day 4 of DSS exposure, but were no different between the geno-
types (Fig. 3C).
In summary, the G2A2/2 mice, relative to WT mice, showed
significantly worsened disease on all measures, and showed in-
creased numbers of monocytes and eosinophils and fewer
CD4 lymphocytes recruited to injured colons than WT mice.
Differences in cytokines present in colon tissues appeared to be
elevated IL-6 and IL-5, and diminished IFN-g in the G2A2/2
mice relative to WT.
Worsened colitis in G2A-deficient mice is driven by
proinflammatory monocytes in an eosinophil-dependent
manner
Earlier studies from several groups have shown that monocyte
populations infiltrating the inflamed colon exhibit marked het-
erogeneity, with transition over time from a so-called proin-
flammatory phenotype to an anti-inflammatory phenotype (26, 27).
FIGURE 2. G2A2/2 mice show altered recruitment of immune cells over the course of DSS-induced colitis. (A–F) Immune cell types were determined
by flow cytometry following digestion, as described in Materials and Methods. Gating strategy is described in Materials and Methods and Supplemental
Fig. 1E. Note differences in scale. Square symbols denote myeloid cells tagged with i.v. anti-CD45 (see Materials and Methods). Data represent
mean 6 SEM, n = 8–10. *p , 0.05, **p , 0.01 compared with WT.
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Proinflammatory Ly6ChiMHCII2 monocytes are initially recruited
from the blood to the tissues and have been shown to make TNF-a
in DSS colitis, and over time, they begin to lose Ly6C expression
and gain MHCII expression. These Ly6CintMHCII+ monocytes
acquire anti-inflammatory features, as they have been shown to
produce IL-10 (26, 27). In the G2A2/2 mice, the number of
proinflammatory monocytes (Ly6ChiMHCII2) was significantly
higher by day 6 of DSS-induced colitis relative to WT (Fig. 4A).
The number of monocytes staining for intracellular TNF-a were
also significantly more numerous in the G2A2/2 mice (Fig. 4B).
In contrast, numbers of Ly6CintMHCII+ monocytes were no dif-
ferent between the genotypes. We were unable to identify IL-10
staining in monocytes of either genotype, attesting to the difficulty
of intracellular staining for this cytokine, and, as noted above, no
differences between genotypes were observed in levels of IL-10
measured in colonic tissue.
Proinflammatory monocytes are thought to contribute to host/
biome responses and injury in DSS-induced colitis (24, 25). For
example, both the CCR22/2 mice and mice in which monocytes
have been depleted show improvement in various endpoints in
DSS colitis (27, 29). As such, the potential role of proinflam-
matory monocytes in driving the excess inflammation seen in the
G2A2/2 mice was assessed using a monocyte-depleting Ab. As
shown in Fig. 5A, prior treatment with the anti-CCR2 (MC-21) Ab
efficiently depleted monocytes from both genotypes regardless of
phenotype. With monocyte depletion, the exacerbated disease
activity and colon shortening in the G2A2/2 mice were reduced to
that seen in WT animals (Fig. 5B, 5C). Monocyte depletion in WT
mice was associated with a trend toward lessened disease activity
consistent with the findings by others (27, 30).
Notably, monocyte depletion abolished excess eosinophil num-
bers in the G2A2/2 mice (Fig. 5D), indicating that monocytes
can play a role in the accumulation of eosinophils, as reported
previously (29). Eosinophil accumulation in colonic tissue of
DSS-treated WT mice was unchanged with monocyte depletion.
No changes were seen in neutrophil or lymphocyte numbers in
either genotype with monocyte depletion.
Using an Ab directed to IL-5 (clone TRFK5), excess eosinophil
numbers were depleted in the G2A2/2 mice (Fig. 6A), and their
exacerbated colon shortening and disease activity were significantly
reduced to that of WT mice (Fig. 6B, 6C). Of note, eosinophils in
FIGURE 3. Loss of G2A receptor signaling results in altered cytokine
production. IL-6, IL-5 (A), and IFN-g (B) were among cytokines measured
in homogenates from a 1-cm section of the distal colon by MesoScale
Discovery Platform 6 d after administration of 3% DSS. Data represent
mean 6 SEM, n = 10. **p , 0.01, ***p , 0.001 versus WT. (C) LysoPC
was quantified by liquid chromatography–tandem mass spectrometry in
whole colon tissue over a time course of DSS colitis and showed a sig-
nificant increase 4 d after administration of DSS. No difference was de-
tected between the genotypes. Data represent mean 6 SEM; n = 6.
FIGURE 4. G2A2/2 mice have more TNF-a+ proinflammatory mono-
cytes during DSS-induced colitis than WT. (A) Representative flow
cytometry plot demonstrating gating strategy to separate Ly6ChiMHCII2
from Ly6CintMHCII+ monocytes (left). Total Ly6ChiMHCII2 and Ly6Cint
MHCII+ monocytes were determined by multiplying the percentage by the
total number of monocytes from Fig. 2 (right). (B) Representative flow plot
demonstrating intracellular TNF-a staining in the Ly6C-positive mono-
cytes (left). Gray dots are isotype Ab controls. Total numbers of TNF-a+
monocytes (right) were determined by multiplying the percentage of
TNF-a+ cells by the total number of monocytes from Fig. 2. Data repre-
sent mean 6 SEM, n = 10. *p , 0.05, **p , 0.01 compared with WT.
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WT mice were also reduced following anti–IL-5 Ab administration.
However, in WT mice, colon shortening was worsened, and their
disease activity was exacerbated, consistent with our previously
published data (31). Thus, subpopulations of eosinophils clearly
play differing roles in DSS-induced colitis depending on genotype,
mediating the worsened colitis in G2A2/2 mice, whereas amelio-
rating colitis in WT (see Discussion).
The role of IFN-g production in G2A2/2 disease activity
IFN-g production in colitis is thought to come from several
lymphocyte populations (32, 33). Given the lower levels mea-
sured in inflamed colonic tissues of the G2A2/2 mice (Fig. 3),
possibly related to the reduced numbers of CD4 lymphocytes
recruited to the colons of these mice (Fig. 2), we further investi-
gated the role of IFN-g. First, a time course of Ifng gene ex-
pression in whole colon tissue was assessed. Ifng mRNA in
colonic tissues increased in WT mice by day 4 and was signifi-
cantly elevated over baseline by day 6 (Fig. 7A). This increase was
not evident in G2A2/2 mice. The differences in the levels of
IFN-g in inflamed colons between the two genotypes (Fig. 3) were
also evident in sera (Fig. 7B).
Next, we assessed stimulated production of IFN-g from colonic
digest cells. Cells (106) from DSS day 6 colon digests were cul-
tured in media and stimulated with PMA and ionomycin for 4 h,
and IFN-g was assessed in the supernatants by ELISA. As shown,
FIGURE 5. Depletion of monocytes limits disease severity in G2A2/2
mice and reduces eosinophil numbers. Mice were treated with anti-CCR2
clone MC-21 (MC-21) or isotype Ab, as described in Materials and
Methods. (A) Monocytes were depleted with MC-21. Left, Representative
flow plot demonstrating efficient depletion of monocytes. Right, Total
monocytes were significantly reduced in MC-21–treated animals (versus
isotype treated) for both genotypes. (B) Disease activity index (DAI) was
determined in MC-21– or isotype-treated mice over the time course of DSS
exposure (left) and in an expanded representation for day 6 of DSS ex-
posure (right). Dotted line indicates maximum DAI score. (C) Colon length
was determined at day 6 following administration of DSS in MC-21– and
isotype-treated animals. Dotted line represents colon length of water
control animals. (D) Total numbers of eosinophils were determined with
and without monocyte depletion with MC-21. Data represent mean 6 SEM,
n = 10. *p, 0.05, **p, 0.01 compared with WT isotype, WT MC-21, and
G2A2/2 MC-21.
FIGURE 6. Treatment with anti–IL-5 (a-IL-5) reduces eosinophil num-
bers and disease severity in G2A2/2 mice. Mice were treated with anti–IL-5
clone TRFK5 or isotype control Ab, as described inMaterials and Methods.
(A) Total eosinophils at day 6 were determined as described in Fig. 2. (B)
Colon length normalized to initial body weight and (C) disease activity
(DAI) determined over the time course of DSS exposure (left) and in an
expanded representation for day 6 after DSS exposure (right). Dotted line
represents colon length per initial body weight from water control animals
(B) or maximum DAI score (C). Data represent mean 6 SEM, n = 10.
**p, 0.01 compared with WT isotype, WTanti–IL-5, and G2A2/2 anti–IL-5,
*p , 0.05 compared with G2A2/2 anti–IL-5 or WT isotype, #p , 0.05
compared with WT isotype, G2A2/2 isotype, and G2A2/2 anti–IL-5, †p, 0.01
compared with WT isotype or G2A2/2 anti–IL-5.
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IFN-g was profoundly deficient in culture supernatants from
G2A2/2 mice in comparison with WT mice (Fig. 7C), whereas
stimulated TNF-a levels were not different between the geno-
types. By contrast, PMA/ionomycin-stimulated spleen cells from
naive G2A2/2 and WT mice produced similar amounts of IFN-g
(Fig. 7D), showing that the ability to produce IFN-g was not
generally deficient in the G2A2/2 animals. However, as hypoth-
esized, only WT and not G2A2/2 splenocytes made additional
IFN-g in response to lysoPC treatment. To better define potential
sources of IFN-g in the inflamed colons, colon digest cells were
then stimulated as above in the presence of brefeldin A, stained for
CD4 and intracellular IFN-g, and analyzed by flow cytometry.
Under these conditions, intracellular IFN-g was evident in a
proportion of stimulated CD4+ and CD42 lymphocytes (Fig. 7E).
When expressed as a percentage of total lymphocytes for
each genotype, fewer were positive for IFN-g in the G2A2/2
animals than in WT (Fig. 7E). Thus, it appears likely that
WT lymphocytes, most notably CD4+ T cells, but also CD42
lymphocytes, are recruited to injured colons, and are primed/
stimulated in a G2A-dependent manner for enhanced IFN-g pro-
duction. In the absence of G2A signaling, fewer numbers of CD4+
lymphocytes are recruited during colitis, and these lymphocytes,
as well as recruited CD4- lymphocytes, are deficient in their
production of IFN-g.
Ly6CintMHCII+ monocytes, in some settings, have been shown
to bear an IFN-g response signature (34, 35). We hypothesized
that deficient IFN-g in the colon of the G2A2/2 mice might
contribute to a blockade or delay in the transition of Ly6Chi
MHCII2 proinflammatory monocytes to Ly6CintMHCII+ anti-
inflammatory monocytes. To address this, G2A2/2 mice were
treated with IFN-g (5 mg) on days 3 and 5 of DSS exposure with
harvest of the animals at day 6. Following IFN-g treatment, the
total numbers of monocytes in the colons of G2A2/2 were un-
changed and remained elevated compared with WT colons
(Fig. 8A). However, following IFN-g treatment, the proportion of
monocytes that were Ly6ChiMHCII2 was significantly lower, and
the Ly6CintMHCII+ significantly greater in G2A2/2 mice
(Fig. 8A, Supplemental Fig. 2A). In support of the hypothesis that
transition to Ly6CintMHCII+ is associated with a less inflamma-
tory program, the number of monocytes staining positive for in-
tracellular TNF-a was also reduced. Colon tissue IL-6 appeared to
be reduced following IFN-g treatment of G2A2/2 mice, although
the difference did not reach significance (Fig. 8B). Colon tissue
IL-10 was no different (data not shown). IL-5 in colon tissues was
significantly reduced following IFN-g treatment, and, accordingly,
eosinophil numbers were reduced to that seen in WT colon tissues
(Fig. 8C).
Importantly, the exacerbated colitis in the G2A2/2 mice was
significantly ameliorated with IFN-g treatment (Fig. 8D). Disease
activity, colon lengths, and histology were all improved in G2A2/2
mice with measures of each being similar to those seen in the
WT mice, as well as substantially mimicking the effects of
monocyte and eosinophil depletion (Figs. 5, 6). Identical treatment
of WT mice with IFN-g resulted in minimal reductions in disease
FIGURE 7. IFN-g production is deficient in colon tissues and stimulated
colonic lymphocytes from G2A2/2 mice. (A) Ifng gene expression was
determined by quantitative PCR from sections of distal colon over the time
course of DSS-induced colitis. Data represent mean 6 SEM, n = 10. *p ,
0.05 compared with G2A2/2. (B) Serum was collected from whole blood
from naive mice or at day 6 after administration of DSS, and IFN-g
concentration was determined as described in Fig. 3. Data represent
mean 6 SEM, n = 6–8. *p , 0.05. (C) IFN-g and TNF-a were measured
by ELISA in cell-free supernatants following stimulation of cells from
digested colons with PMA and ionomycin (P/I) for 4 h. Data represent
mean 6 SEM, n = 10. **p , 0.01 compared with stimulated WT. (D)
IFN-g was measured in cell-free supernatants following stimulation of
splenocytes from naive animals, as described in (C), in the presence or
absence of 10 mM lysoPC (LPC). Data are displayed as fold of stimulated
WT and represent mean 6 SEM, n = 4–6. **p , 0.01 compared with
stimulated WT, stimulated G2A2/2, and stimulated G2A2/2 + LPC.
(E) Intracellular IFN-g staining in control and stimulated (PMA and ion-
omycin for 4 h) colon digest cells from day 6 DSS in the presence of
brefeldin A. Representative flow plots demonstrating intracellular IFN-g
staining in control or stimulated B2202SSClo CD4+ and CD42 lympho-
cytes (left). Gray dots are stained with isotype control Ab. The percentage
of stimulated B2202CD42 or B2202CD4+ lymphocytes staining positive
for IFN-g in WT or G2A2/2 mice is shown (right). Data represent mean
6 SEM, n = 10. *p , 0.05, **p , 0.01 compared with WT.
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activity, colon shortening, and cellular infiltration, suggesting opti-
mal effects from endogenously produced IFN-g (Supplemental Fig.
2B–D).
Discussion
Production of lysoPC accompanies epithelial cell injury in the
airway (9, 10) and the intestine (11, 12) and results in a variety of
proinflammatory actions mediated through the G protein–coupled
receptor G2A present on recruited inflammatory cells (8). Al-
though our investigation of colitis in G2A2/2 mice began with the
hypothesis that loss of this receptor would be therapeutic, this
hypothesis is refuted with unequivocal evidence that the G pro-
tein–coupled receptor serves to dampen inflammation in this
model. Key elements were identified in this investigation, as fol-
lows: excess inflammation and disease activity in the G2A2/2 mice
were attributable to activities of proinflammatory subpopulations of
monocytes and eosinophils, and, surprisingly, injury from these
effector cells was ultimately the result of diminished production
of IFN-g.
IFN-g is elevated in colonic tissues in human inflammatory
bowel disease as well as in animal colitis models (4–7). IFN-g is
generally thought of as a quintessential proinflammatory cytokine
required in many instances for innate and Th1 adaptive immunity,
although its effects are protean. Genetic ablation of IFN-g or its
neutralization has been shown by some (32, 36) but not other
investigators (37) to ameliorate disease severity in the DSS model.
These mixed findings and our data, in this work, may help to
explain the lack of therapeutic success of blocking the action of
IFN-g in human IBD (38).
The sources of IFN-g in DSS colitis are thought to be
various lymphocyte populations, including both CD4 and CD8
cells after exposure to inflamed colonic epithelial cells (32). We
FIGURE 8. Provision of IFN-g to
G2A2/2 mice enhances anti-inflamma-
tory monocyte programming, reduces
IL-5 and eosinophils, and limits
disease severity. G2A2/2 mice were
treated with 5 mg IFN-g on days 3
and 5 after administration of 3%
DSS and harvested at day 6. (A)
Total monocytes, Ly6ChiMHCII2
monocytes and Ly6CintMHCII+
monocytes, and TNF-a+ monocytes
were determined, as described in
Figs. 2 and 4. Data represent mean
6 SEM; n = 15, *p , 0.05, **p ,
0.01. (B) IL-6 concentration in a
distal section of colon tissue was
determined, as described in Fig. 3.
Data represent mean 6 SEM; n = 6,
*p , 0.05. (C) IL-5 concentration
was determined, as described in (B),
and total eosinophil numbers were
determined, as described in Fig. 2.
Data represent mean 6 SEM, n =
15. *p , 0.05, **p , 0.01. (D)
Disease activity (DAI) (left), colon
length (middle), and total histologic
index (right) were determined, as
described in Fig. 1. Dotted line re-
presents maximum DAI score (left)
or colon length of water control an-
imals (middle). Lower, Represen-
tative histologic images of WT,
G2A2/2, or IFN-g–treated G2A2/2
mice. Data represent mean 6 SEM,
n = 15. *p , 0.05 compared with
WT, **p , 0.01 compared with WT
and G2A2/2 IFN-g, #p , 0.01
compared with G2A2/2.
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have shown deficient recruitment of CD4 lymphocytes to inflamed
colons in the G2A2/2 mice, and that recruited lymphocyte pop-
ulations, both CD4+ and CD42, seem to produce less IFN-g in
response to stimulation than lymphocytes of WT mice (Fig. 7).
The most likely explanation is that the G2A2/2 lymphocytes
cannot be primed/activated for enhanced production of IFN-g by
lysoPC (18). In this regard, we note that the G2A receptor can also
respond to other signals aside from lysoPC, for example, lysoPS
(39). We measured lysoPS and found it present at very low levels
in both genotypes for most of the course of colitis (data not
shown). Although we cannot rule out a contribution in WT mice
from lysoPS/G2A anti-inflammatory modulation of monocyte
programming (23), to our knowledge only lysoPC/G2A signaling
has been associated with IFN-g production by lymphocytes (16,
18). Of note, in recent studies of DSS colitis and ulcerative colitis
in humans, it was shown that lysoPC ultimately declines with
disease chronicity (12, 40), and, given our findings, we hypothe-
size this may result in deficient G2A signaling and the resulting
inflammatory events demonstrated in this work.
Despite the defined effect of G2A signaling on dampening the
degree of colonic inflammation and disease in this model, a key
future question is the specific cell target(s) for the G2A effect and
the proposed effect of lysoPC stimulation. However, even in the
absence of isolating G2A deficiency on one cell type or another, the
approach taken in this study allowed us to elucidate specific roles
and a hierarchy for the key effector cells/mediators. First, deple-
tion of either eosinophils or monocytes using depleting Abs, or
the institution of IFN-g treatment, all resulted in nearly iden-
tical amelioration of the enhanced disease activity, histological
changes, and colon shortening in the G2A2/2 mice (comparing
Figs. 5, 6, and 8). Thus, a common pathway is suggested. Further
support for this comes from the observation that both monocyte
depletion and IFN-g treatment resulted in elimination of excess
eosinophil numbers in the G2A-deficient mice, whereas eosinophil
depletion in these mice had no obvious effect on these other key
elements. This allows us to position eosinophils as a candidate
final effector cell responsible for excess colonic injury in the
G2A2/2 mice. An important observation is that, whereas deple-
tion of excess eosinophils in the G2A2/2 mice was ameliorative of
heightened inflammation and disease activity, depletion of eosin-
ophils in WT animals exacerbated injury. This latter finding has
been recently published and is attributed to deficient eosinophil
15-lipoxygenase production of protectin D1 (31). Furthermore,
intestinal eosinophils are present in the colon in homeostasis in both
genotypes and not fully amenable to this depletion strategy. These
data highlight the observations that eosinophils can play many
immunomodulating roles differing in intestinal homeostasis and
disease states (41, 42). Clearly, their activation status, numbers, and
location are likely of great importance to such heterogeneity and the
different roles that they play, and the potential role of G2A on
eosinophils, themselves, are all key areas for further investigation.
Perhaps the most surprising finding in this investigation of col-
itis in the G2A2/2 mice was the prominent role of IFN-g in the
anti-inflammatory programming of recruited monocytes. Several
groups have shown that monocytes recruited to the inflamed colon
in the DSS model exhibit marked heterogeneity (26, 27). They
are known to progress from Ly6Chi MHCII2 TNF-a–producing
monocytes through loss of Ly6C and gain of MHCII in association
with IL-10 production (26, 27). We have shown that treatment
with IFN-g, although not affecting overall numbers of monocytes
in G2A2/2 mice, appeared to enhance the acquisition of MHCII
on monocytes in the G2A2/2 mice (Fig. 8A, Supplemental Fig.
2A), an effect consistent with actions of IFN-g in other contexts
(33, 43). We were unable to replicate enhanced intracellular
staining of IL-10 in the resulting Ly6CintMHCII+ monocytes in
either WT or G2A2/2 mice (data not shown), and levels of IL-10,
known to be produced by other sources in colitis (44–46), were not
different between G2A2/2 and WT colitic mice. Importantly, the
enhanced transition of monocytes to Ly6CintMHCII+ driven by
IFN-g was accompanied by diminished numbers of TNF-a+
monocytes (Fig. 8A). TNF-a clearly plays an important role in the
DSS model (47, 48) and human IBD, where it is a proven thera-
peutic target (49–51). This anti-inflammatory activity of IFN-g
on monocytes adds to accumulating evidence that IFN-g may dis-
play inflammation-mitigating properties in mucosal inflammation
models (52). IFN-g has, for example, been shown to mediate anti-
inflammatory properties through induction of IDO 1 (53), regu-
lation of the methylation response (54), and induction of epithelial
IL-10Rs (20) supportive of healing responses by the epithelium.
We also note that anti-inflammatory activities of IFN-g on
monocytes have also recently been described in the context of
gastrointestinal infection (43).
In summary, the G protein–coupled receptor G2A appears to be
important in limiting disease severity in this model of acute colitis
driven by insult to the epithelium and propagated by innate host
response to microflora. G2A signaling does so through a complex
interaction of IFN-g production, monocyte programming, and
eosinophil-induced injury. Investigation of its roles in chronic intestinal
inflammation, other models of IBD, and other models of epithelial
insult, for example, airways, is likely to provide new mechanistic in-
sights and possible therapeutic targets following mucosal injury.
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